About Nimble Science
Nimble Science is a Healthcare company based in Calgary (Canada) founded in 2018 by Sabina Bruehlmann and Joseph Wang. It operates as a developer of personalised medicine for gut health. Nimble Science has raised $2.7 million across 1 funding round from investors including University of Calgary, Fusion Fund and First Spark Ventures. Its chief executive is Sabina Bruehlmann. Nimble Science offers products and services including SIMBA GI Platform, Biopharma Services, and Nutrition Services. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Nimble Science was founded in 2018 in Calgary, Canada. Operations center on biotechnology for gut health, where probiotic-based medicines, novel capsules, and small intestine sampling tools are developed. Gut microorganisms are sequenced and mapped, while biomarkers are collected to enable personalised treatments. Diagnostic innovations are also pursued to support microbiome analysis in the healthcare sector.
- Headquarters Calgary, Canada
- Founders Sabina Bruehlmann, Joseph Wang
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nimblesci.com
- Social LinkedIn
- Total Equity Funding$2.7M (USD)
in 1 rounds
- Latest Funding Round$2.7M (USD), Seed
Apr 2023
- InvestorsUniversity of Calgary
& 10 more
Products & Services of Nimble Science
Nimble Science offers a comprehensive portfolio of products and services, including SIMBA GI Platform, Biopharma Services, and Nutrition Services.
Autonomous capsule for collecting multi-omic data from small intestine.
Partnerships for biopharma and nutrition data analysis.
Support for validating microbiome changes in nutrition.
Funding Insights of Nimble Science
Nimble Science has successfully raised a total of $2.7M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.7 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.7M
- Total Rounds 1
- Last Round Seed — $2.7M
- First Round $2.7M
(Apr 2023)
- Investors Count 11
All 1 funding rounds of Nimble Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $2.7M | Seed | – | Fusion Fund |
11 investors in total: 11 institutional.
Investors in Nimble Science
Nimble Science has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Calgary, Fusion Fund and First Spark Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in early-stage startups focusing on healthcare, AI, and industrial technology. | – | fusionfund.com | - | |
A venture capital fund focused on deep tech innovations is managed. | – | firstsparkventures.com | - | |
Venture capital investing and portfolio management services for accredited investors. | – | av.vc | - | |
Venture capital fund focused on tech sectors | – | joyancepartners.com | San Francisco, United States | |
Venture capital funding is provided to technology startups by Adara Ventures. | – | adara.vc | Madrid, Spain | |
Diversified sectors are targeted by Startup TNT's angel investment network. | – | startuptnt.com | Edmonton, Canada | |
Early-stage companies are invested in by BoxOne Ventures. | – | boxone.xyz | Montreal, Canada | |
ThresholdImpact is engaged in sustainable impact investing. | – | thresholdimpact.com | - | |
- | – | blueskyequities.com | - | |
A leading Canadian university offering diverse academic programs. | 1966 | ucalgary.ca | Calgary, Canada |
Investor details for Nimble Science
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nimble Science
4 people are tracked at Nimble Science (3 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Sabina Bruehlmann | Co-Founder & CEO | Leadership |
Joseph Wang | Co-Founder | Leadership |
Marsha Bures | Director of Quality and Regulatory | Leadership |
Cedoljub Bundalovic-Torma | Senior Scientist, Data And Bioinformatics | Team |
Complete people profiles for Nimble Science
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nimble Science
2 dated milestones of Nimble Science across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nimble Science is founded.
- Funding First funding round of $2.7M.
Competitors of Nimble Science
Nimble Science has 9 listed competitors in our database, 8 of them funded. They include Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of Nimble Science
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nimble Science
The website of Nimble Science (nimblesci.com) receives about 8.2K visits a month.
- Monthly visits8.2K
▲ 97.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Nimble Science (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nimble Science
Complete news archive for Nimble Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nimble Science
Nimble Science was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Nimble Science is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
Sabina Bruehlmann is the current CEO of Nimble Science. They have also founded this company.
Nimble Science is a funded company, having raised a total of $2.7M across 1 funding round to date. The company's 1st funding round was a Seed of $2.7M, raised on Apr 2023.
Nimble Science was founded in 2018 in Calgary, Canada. Operations center on biotechnology for gut health, where probiotic-based medicines, novel capsules, and small intestine sampling tools are developed. Gut microorganisms are sequenced and mapped, while biomarkers are collected to enable personalised treatments. Diagnostic innovations are also pursued to support microbiome analysis in the healthcare sector.
Nimble Science's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Nimble Science offers SIMBA GI Platform, Biopharma Services, and Nutrition Services.
Nimble Science has 11 investors. Key investors include University of Calgary, Fusion Fund, First Spark Ventures, Alumni Ventures, and Joyance Partners.